| Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study Of PF-04427429 In Healthy Women Volunteers (NCT01511497) | Pfizer | 2011-10-01 |
| BOTOX® Prophylaxis in Patients With Chronic Migraine (NCT01432379) | Allergan | 2011-09-09 |
| A Combination Product of Sumatriptan and Naproxen Sodium Versus Single-entity Oral Triptans: An Analysis of Real World Data (NCT01381523) | GlaxoSmithKline | 2010-11-01 |
| Impact of Migraine on Work Productivity in Patients Treated With a Combination Product Containing Sumatriptan and Naproxen Sodium or Triptan Monotherapy (NCT01381497) | GlaxoSmithKline | 2010-03-01 |
| Non-steroidal Anti-inflammatory Drugs Alone or With a Triptan and Reports of Transition From Episodic to Chronic Migraine (NCT01435941) | GlaxoSmithKline | 2009-09-01 |
| Treximet ™ Pharmacy Budget Impact Model Database Validation Study (NCT01332500) | GlaxoSmithKline | 2009-07-01 |
| Dose-ranging Study of Oral COL-144 in Acute Migraine Treatment (NCT00883051) | Eli Lilly and Company | 2009-07-01 |
| Effect of Metoclopramide Versus Sumatriptan for Emergency Department Treatment of Migraine Headache (NCT01791400) | Isfahan University of Medical Sciences | 2009-07-01 |
| Special Drug Use Investigation for AMERGE® Tablet (Long-term) (NCT01332383) | GlaxoSmithKline | 2009-05-01 |
| MedlinePlus Health Prescriptions: Developing a Pragmatic Approach for Clinic Use (NCT01050465) | University of Missouri-Columbia | 2009-05-01 |
| Drug Use Investigation for AMERGE (Naratriptan Hydrochloride) Tablet (NCT01376193) | GlaxoSmithKline | 2009-04-01 |
| An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over Twelve Months (NCT00806546) | NuPathe Inc. | 2009-02-01 |
| An Open-Label Study to Evaluate the Safety of NP101 in the Treatment of Acute Migraine Over 12 Months (NCT00792103) | NuPathe Inc. | 2009-01-01 |
| The Efficacy and Tolerability of NP101 Patch in the Treatment of Acute Migraine (NCT00724815) | NuPathe Inc. | 2009-01-01 |
| Migraine Study in Adolescent Patients (NCT00843024) | GlaxoSmithKline | 2008-12-01 |
| Topiramate and Cerebrovascular Response in Migraineurs (NCT02424318) | SMG-SNU Boramae Medical Center | 2008-12-01 |
| A Pharmacokinetic Study to Evaluate TREXIMET in Adolescents With Migraine and Healthy Subjects Administered at Three Doses. (NCT00989625) | GlaxoSmithKline | 2008-11-04 |
| Phase I, Open Label, Single-Dose, Four Way Crossover Study to Compare the PK of NP101 With Oral Imitrex® (50mg) in Migraine Subjects During an Acute Migraine Attack and During a Non-Migraine Period (NCT00723983) | NuPathe Inc. | 2008-11-01 |
| A Study to Determine the Effect of Sumatriptan and Naproxen Sodium Combination Tablet, Sumatriptan Tablet, and Naproxen Sodium Tablet on Blood Pressure When Treating Migraine Headaches That Occur During a 6-month Period (NCT00792636) | GlaxoSmithKline | 2008-11-01 |
| Relative Bioavailability of a Single Dose of BI 44370 Tablet During and Between Migraine Attacks (NCT00743015) | Boehringer Ingelheim | 2008-09-01 |
| BI 44370 TA in Acute Migraine Attack (NCT00751803) | Boehringer Ingelheim | 2008-08-01 |
| Prevention Study in Adult Patients Suffering From Migraine Headaches (NCT00742209) | XenoPort, Inc. | 2008-08-01 |
| Phase 3 Study of MAP0004 in Adult Migraineurs (NCT00623636) | Allergan | 2008-07-01 |
| Phase I Open Label Single-Dose Study to Compare the Pharmacokinetics of NP101 Healthy Volunteers (NCT00720018) | NuPathe Inc. | 2008-06-01 |
| An Open-label, Randomized, 3-period Crossover Study to Evaluate Sumatriptan Pharmacokinetics for a TREXIMA™ (Sumatriptan Succinate / Naproxen Sodium) Tablet Followed by IMITREX® (Sumatriptan Succinate) (NCT00875784) | GlaxoSmithKline | 2008-05-06 |
| Telcagepant (MK-0974) Treatment of Migraine in Participants With Stable Vascular Disease (MK-0974-034) (NCT00662818) | Merck Sharp & Dohme LLC | 2008-03-17 |
| TREXIMET® Versus Butalbital-containing Combination Medications for the Acute Treatment of Migraine in Adults (NCT00573170) | GlaxoSmithKline | 2008-02-01 |
| Drug Study in Pediatric Subjects With Migraines (MK0462-083 AM1) (NCT00604812) | Organon and Co | 2007-12-17 |
| Study to Evaluate the Safety, Tolerability, and Blood Pressure Effect of an Oral Dose of Sumatriptan Alone and in Combination With MK-0974 (Telcagepant) in Migraine Patients (0974-026) (NCT00701389) | Merck Sharp & Dohme LLC | 2007-11-20 |
| A Study of Gastric Delay in Migraine Patients (3207-003) (NCT00548353) | Merck Sharp & Dohme LLC | 2007-08-01 |
| Long-Term Safety of Treximet (Sumatriptan/Naproxen Sodium) for Migraine in Adolescents (NCT00488514) | GlaxoSmithKline | 2007-07-13 |
| Vestibular System in Migrainous Vertigo Patients (NCT00901953) | University of Bergen | 2007-05-01 |
| Efficacy and Safety Clinical Trial of Intranasal AST-726 for the Prevention of Migraine (NCT00285402) | Ariston Pharmaceuticals, Inc. | 2007-05-01 |
| Efficacy of Pregabalin in Migraine Prevention (NCT00447369) | Hospital Militar del General Luis Felipe Brieba Aran | 2007-05-01 |
| Caffeine/Propranolol Intervention for Acute Migraine (NCT01080677) | Stanford University | 2007-01-01 |
| A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 2 of 2) (NCT00382993) | GlaxoSmithKline | 2006-12-01 |
| A Study of Combination Product (Sumatriptan Succinate and Naproxen Sodium) in Migraine Subjects Who Report Poor Response or Intolerance to Short Acting Triptans (Study 1 of 2) (NCT00383162) | GlaxoSmithKline | 2006-11-01 |
| TREXIMA and RELPAX Gastric Scintigraphy Inside and Outside a Migraine (NCT00385008) | GlaxoSmithKline | 2006-09-13 |
| Lippia Alba for Migraine Prophylaxis and Treatment (NCT01259947) | Fabio Carmona | 2006-07-01 |
| Study Of Sumatriptan Succinate Injection Kit In Patients With Migraine or Cluster Headache In Japan (NCT00356603) | GlaxoSmithKline | 2006-06-20 |
| Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as TREXIMA, for Menstrual Migraine in Women With Dysmenorrhea (NCT00329459) | GlaxoSmithKline | 2006-05-01 |
| Menstrual Migraine Treatment With TREXIMET (Formerly Known as TREXIMA) (NCT00329355) | GlaxoSmithKline | 2006-05-01 |
| A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches (NCT00168428) | Allergan | 2006-03-01 |
| A Study Using Botulinum Toxin Type A as Headache Prophylaxis for Migraine Patients With Frequent Headaches (NCT00156910) | Allergan | 2006-02-01 |
| American Migraine Prevention Study (NCT00363506) | Dynamic Health Resources | 2006-01-01 |
| An Adaptive Design Trial Of GW274150 In The Treatment Of Acute Migraine (NCT00319137) | GlaxoSmithKline | 2005-12-01 |
| ESCAPE Migraine Trial (NCT00267371) | Abbott Medical Devices | 2005-11-01 |
| Use Of GW274150 In The Prophylactic Treatment Of Migraine (NCT00242866) | GlaxoSmithKline | 2005-10-01 |
| Treximet (Sumatriptan/Naproxen Sodium), Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks (NCT00240630) | GlaxoSmithKline | 2005-10-01 |
| Study Of Treximet, Formerly Known as Trexima, In The Acute Treatment Of Multiple Migraine Attacks (NCT00240617) | GlaxoSmithKline | 2005-10-01 |
| An Observational Study Evaluating the Safety of Topiramate for the Prevention of Migraine (NCT00297336) | Janssen Cilag Pharmaceutica S.A.C.I., Greece | 2005-03-01 |
| Sumatriptan and Naratriptan Pregnancy Registry (NCT01059604) | GlaxoSmithKline | 2001-12-01 |
| Drug Use Investigation for IMIGRAN Tablet (NCT01376141) | GlaxoSmithKline | 2001-09-01 |
| Efficacy, Safety, Tolerability and Pharmacokinetics of BIBN 4096 BS Versus Placebo in the Treatment of a Single Attack of Acute Migraine Headache (NCT02198339) | Boehringer Ingelheim | 1999-02-01 |
| Efficacy and Tolerability of Metamizol in Patients With Episodic Moderate Headache (NCT02183220) | Boehringer Ingelheim | 1998-10-01 |
| Acetylsalicylic Acid (ASA) + Paracetamol + Caffeine Combination Compared With ASA + Paracetamol as Well as ASA, Paracetamol, and Caffeine in Headache Patients (NCT02183688) | Boehringer Ingelheim | 1998-09-01 |
| Long-Term Exposure to Rizatriptan 5-mg and 10-mg Oral Tablet (Combined Extension Protocols MK-0462-022, MK-0462-025, MK-0462-029) (NCT01286207) | Organon and Co | 1995-03-01 |